Scientific Publications
Human Resources for Health 2010, 8:8
Kathryn M Chu, Surgeon, MSF South Africa (BMJ)
October 2009, Journal of the International AIDS Society 2009, 12:23
September 2009, Vol 9, The Lancet
July 2009, Conflict and Health 2009, 3:7
May 2009, PLoS Medicine, Vol 6
March 24, 2009, Conflict and Health 2009, 3:4
March 2009
January 2009, No 18
December 2008, Vol. 98, No. 12 SAMJ
December 02, 2008; 179 (12), CMAJ
November 18, 2008; 179 (11), CMAJ
Global health-care implications of substandard medicines
November 2008, Vol 8, The Lancet
November 2008, Vol 8, The Lancet
November 5, 2008—Vol 300, No. 17, JAMA
October 2008, 8:39, BMC Pediatrics
September 2008, 12(10):1104, The International Journal of Tuberculosis and Lung Disease
Antiretroviral Theraphy and Early Mortality in South Africa
September 2008, 89, Bulletin of the World Health Organisation
September 2008, 89, Bulletin of the World Health Organisation
6 September 2008, Vol 372, The Lancet
2 August 2008, Volume 372, The Lancet
Substandard medicines in resource-poor settings: a problem that can no longer be ignored
August 2008, volume 13 no 8 - Tropical Medicine and International Health
JM Caudron, N Ford, M Henkens, C Mace´, R Kiddle-Monroe and J Pinel
August 2008, volume 13 no 8 - Tropical Medicine and International Health
JM Caudron, N Ford, M Henkens, C Mace´, R Kiddle-Monroe and J Pinel
When Best Practice is Bad Medicine: A new approach to rationing tertiary health services in South Africa
(May 2008, Vol. 98, No. 5- South African Journal of HIV Medicine)
Chris Kenyon, Nathan Ford, Andrew Boulle
(May 2008, Vol. 98, No. 5- South African Journal of HIV Medicine)
Chris Kenyon, Nathan Ford, Andrew Boulle
Tough choices: Tenofovir, Tenders and Treatment
(Summer 2008- South African Journal of HIV Medicine)
Nathan Ford, Andy Gray, W D Francois Venter
(Summer 2008- South African Journal of HIV Medicine)
Nathan Ford, Andy Gray, W D Francois Venter
MSF FACT SHEET: Children and HIV/AIDS
(July 2007- MSF Campaign for Access to Essential Medicines )
(July 2007- MSF Campaign for Access to Essential Medicines )
MDR and XDR-TB in high-prevalence HIV settings
(November 2007 - Eric Goemaere)
(November 2007 - Eric Goemaere)
Report on TB Diagnosis and Drug Sensitivity Testing
(October 2006 -Martine Guillerm, Martine Usdin, James Arkinstall)
(October 2006 -Martine Guillerm, Martine Usdin, James Arkinstall)
Report on Development for New Drugs for TB Chemotherapy
(October 2006 - Martina Casenghi)
(October 2006 - Martina Casenghi)
(The Lancet, Vol 367 March 11, 2006 )
Registration problems for antiretrovirals in Africa
(The Lancet - Vol. 367, Issue 9513, 11 March 2006)
Ford N, Darder M
Ford N, Darder M
(Presentation at the Conference on Retroviruses and Opportunistic Infections - February 2006)
Andrew Boulle
Andrew Boulle
( AIDS. 2004 Apr 9;18(6):887-95.)
David Coetzee Katherine Hildebrand, Andrew Boulle, Gary Maartens, Francoise Louis, Veliswa Labatala, Hermann Reuter, Nonthutuzelo Ntwana and Eric Goemaere
The aim of this analysis is to present the early clinical outcomes for adults in a public-sector ART programme in a primary care setting in a poor urban community in South Africa.
David Coetzee Katherine Hildebrand, Andrew Boulle, Gary Maartens, Francoise Louis, Veliswa Labatala, Hermann Reuter, Nonthutuzelo Ntwana and Eric Goemaere
The aim of this analysis is to present the early clinical outcomes for adults in a public-sector ART programme in a primary care setting in a poor urban community in South Africa.
(AIDS 2004, 18 (suppl 3):S27–S31)
David Coetzee, Andrew Boulle, Katherine Hildebrand, Valerie Asselman, Gilles Van Cutsem and Eric Goemaere
Approaches that optimize adherence to therapy are essential, and remain a key challenge, especially when considering the target of reaching the large numbers of individuals who are in need of ART. Methods used to enhance adherence in the primary care setting have not been well described. The objectives of this paper are to describe the approach used to promote adherence and to present the outcomes in the first primary care public sector ART project in South Africa.
David Coetzee, Andrew Boulle, Katherine Hildebrand, Valerie Asselman, Gilles Van Cutsem and Eric Goemaere
Approaches that optimize adherence to therapy are essential, and remain a key challenge, especially when considering the target of reaching the large numbers of individuals who are in need of ART. Methods used to enhance adherence in the primary care setting have not been well described. The objectives of this paper are to describe the approach used to promote adherence and to present the outcomes in the first primary care public sector ART project in South Africa.
(Tropical Medicine and International Health, volume 9 no 6 pp a11–a15 suppl june 2004) David Coetzee, Katherine Hilderbrand, Eric Goemaere, Francine Matthys and Marleen Boelaert
In 2000, a pilot project was launched in Khayelitsha, South Africa to provide a comprehensive continuum of care for HIV-infected persons, including ART. However it was soon realised that a comprehensive TB/HIV service may be more advantageous due to the large numbers of coinfected patients. The purpose of this paper is to present the initial findings from a review of the HIV and TB services in this primary care setting where ART is provided, in order to assess whether they should be integrated.
In 2000, a pilot project was launched in Khayelitsha, South Africa to provide a comprehensive continuum of care for HIV-infected persons, including ART. However it was soon realised that a comprehensive TB/HIV service may be more advantageous due to the large numbers of coinfected patients. The purpose of this paper is to present the initial findings from a review of the HIV and TB services in this primary care setting where ART is provided, in order to assess whether they should be integrated.
(WHO - Perspectives and practice in antiretroviral treatment – 2003) Médecins sans Frontières, the Department of Public Health at the University of Cape Town, and the Provincial Administration of the Western Cape.
The Khayelitsha ARV treatment project was initiated to demonstrate that treating HIV/AIDS with antiretroviral (ARV) drugs in a primary health care setting and in a resource-limited environment is feasible and replicable. In addition, it aimed to prove that developing countries can provide affordable HIV/AIDS care with low-cost ARV drugs.
After two years, the programme has produced invaluable lessons, which are outlined in this paper.
The Khayelitsha ARV treatment project was initiated to demonstrate that treating HIV/AIDS with antiretroviral (ARV) drugs in a primary health care setting and in a resource-limited environment is feasible and replicable. In addition, it aimed to prove that developing countries can provide affordable HIV/AIDS care with low-cost ARV drugs.
After two years, the programme has produced invaluable lessons, which are outlined in this paper.
(Bulletin of the World Health Organisation, 2005; 83; 489-494)
David Coetzee, Katherine Hilderbrand, Andrew Boulle, Beverley Draper, Fareed Abdullah, & Eric Goemaere
This study aimed to estimate the field efficacy of the PMTCT programme in Khayelitsha, and to provide details on the antiretroviral regimens received by mothers and children.
David Coetzee, Katherine Hilderbrand, Andrew Boulle, Beverley Draper, Fareed Abdullah, & Eric Goemaere
This study aimed to estimate the field efficacy of the PMTCT programme in Khayelitsha, and to provide details on the antiretroviral regimens received by mothers and children.
(Essential Drugs Monitor, Issue 32; 2003)
Toby Kasper, David Coetzee, Francoise Louis, Andrew Boulle, Katherine Hilderbrand
Few areas of public health have generated as much debate, controversy and protest in recent years as the drive to expand access to antiretroviral therapy – the drugs that have transformed AIDS from a death sentence to a chronic condition – in developing countries. Several years ago, it was a futile discussion: with a yearly cost of US$10,000 per patient, there was little possibility of widespread access in developing countries. But, largely as a result of a potent combination of generic competition and activism, prices have plummeted, with triple therapy now being available for as little as US$209 a year1, causing a huge shift in the debate about availability.
Toby Kasper, David Coetzee, Francoise Louis, Andrew Boulle, Katherine Hilderbrand
Few areas of public health have generated as much debate, controversy and protest in recent years as the drive to expand access to antiretroviral therapy – the drugs that have transformed AIDS from a death sentence to a chronic condition – in developing countries. Several years ago, it was a futile discussion: with a yearly cost of US$10,000 per patient, there was little possibility of widespread access in developing countries. But, largely as a result of a potent combination of generic competition and activism, prices have plummeted, with triple therapy now being available for as little as US$209 a year1, causing a huge shift in the debate about availability.
| Weblogs | ||
|
||
|
||
|
||
|
||